Variables	Alteplase dose (mg)[a]				*P* value	Total[b]
	<2.5	2.5	5	10		
Hypertension, no. (%)					0.07	
Yes	14 (82.3)	22 (61.1)	30 (49.2)	6 (50)		75 (58.1)
No	3 (17.6)	14 (38.9)	31 (50.8)	6 (50)		54 (41.9)
Hyperlipidaemia, no. (%)					0.002	
Yes	14 (82.3)	13 (36.1)	20 (32.8	4 (33.3)		51 (39.5)
No	3 (17.6)	23 (63.9)	41 (67.2)	8 (66.6)		78 (60.5)
DM, no. (%)					0.03	
Yes	12 (70.6)	10 (27.8)	21 (34.4)	4 (33.3)		47 (36.4)
No	5 (29.4)	26 (72.2)	40 (65.6)	8 (66.7)		82 (63.6)
CKD, no. (%)					0.003	
Yes	7 (41.2)	5 (13.9)	4 (6.6)	3 (25)		19 (14.7)
No	10 (58.8)	31 (86.1)	57 (93.4)	9 (75)		110 (85.3)
ESRF; patients on dialysis, no. (%)					0.03	
Yes	3 (17.6)	4 (11.1)	1 (1.6)	0		8 (6.2)
No	14 (82.4)	32 (88.9)	61 (98.4)	12		121 (93.8)
Anaemia, no. (%)					0.02	
Yes	8 (47.1)	9 (25.0)	8 (13.1)	3 (25.0)		29 (22.5)
No	9 (52.9)	27 (75.0)	53 (86.9)	9 (75.0)		100 (77.5)
CCI score, no. (%)					0.0001	
Mean (SD)	6.4 (3.7)	3.3 (3.2)	2.6 (2.4)	3 (3.1)		3.3 (3.1)
Median (minimum, maximum)	7 (0, 13)	2.5 (0, 12)	2 (0, 8)	1.5 (0, 10)		2 (0, 13)

CCI: Charlson comorbidity index; CKD: chronic kidney disease; DM: diabetes mellitus; ESRF: end-stage renal failure; SD: standard deviation

[a] Three subjects had no record of alteplase dose.

[b] All 129 subjects were included.